Effects of prolonged-release fampridine on multiple sclerosis-related gait impairments. A crossover, double-blinded, placebo-controlled study.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical biomechanics"
DOI: 10.1016/j.clinbiomech.2021.105382
Abstract: BACKGROUND People with multiple sclerosis have reduced walking speed and impaired gait pattern. Prolonged release-fampridine is a potassium channel blocker that improves nerve conduction in patients with multiple sclerosis, leading to walking benefits. Whether fampridine… read more here.
Keywords: prolonged release; multiple sclerosis; fampridine; release fampridine ... See more keywords